Genedrive PLC (LON:GDR) has supplied units and assays to the US Department of Defense (DoD) for field trials as part of its US$7.8mln development programme.
Officials will assess its potential to check for hazards such as biological warfare agents.
"We are now working with the DoD on tests in the field to confirm the results we've seen so far on Genedrive's robustness and the accuracy of the tests,” said chief executive David Budd.
As well as being smaller and lighter than the current technology, the device is also quick and more flexible with assays for multiple different agents.
"The goal of the programme is to use the key characteristics of Genedrive, its portability and flexibility, to develop a device and test combination that can potentially be widely deployed in the field both for homeland protection and across the world,” added CEO Budd.
“Our cartridges detect multiple agents but are small enough to fit in a pocket.
“The device weighs less than one kilogram and is relatively low cost meaning multiple units could be bought and put into use.”
Currently, Genedrive is being used in India as a quick and easy-to-use test for tuberculosis.